Q&A clinic on Product Management Service (PMS) Product User Interface - 23 July 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 July 2024, 10:00 (CEST) to 23 July 2024, 10:30 (CEST)

Scientific advice and protocol assistance adopted during the CHMP meeting 24-27 June

Q&A clinic on Product Management Service (PMS) Product UI and API , European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 16 July 2024, 10:00 (CEST) to 16 July 2024, 10:30 (CEST)

EMEA-003268-PIP01-22

EMEA-003270-PIP01-22

EMEA-002908-PIP02-22

EMEA-002559-PIP08-23

Opinion/decision on a Paediatric investigation plan (PIP): Spevigo, Spesolimab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Dermatology, PIP number: P/0247/2023

Post-authorisation measures (recommendations, conditions and specific obligations): veterinary medicines

Agenda of the CVMP meeting 16-18 July 2024